Neoplasms

Symptoms and General Pathology

All Conditions

Digestive System Diseases

Gland and Hormone Related Diseases

Rare Diseases

Neoplasm Metastasis

Pancreatic Neoplasms

Neoplastic Processes

Pancreatic Cancer

Antineoplastic Agents

All Drugs and Chemicals

Herbal and Botanical

Amino Acids

Pembrolizumab

Cetuximab

Adagrasib

Afatinib

Antineoplastic Agents, Immunological

Immune Checkpoint Inhibitors

Tyrosine Kinase Inhibitors

Protein Kinase Inhibitors

Enzyme Inhibitors

Cola

Tyrosine

Dose escalation of MRTX849 to determine maximum tolerated dose

Expansion cohort to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of MRTX849 to recommend Phase 2 regimens

Separate cohorts of patients stratified by histological diagnosis, prior treatment history or co-mutation status (e.g., STK11) for evaluation of clinical activity of MRTX849

Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with pembrolizumab in patients with NSCLC

Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with cetuximab in patients with CRC

Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with afatinib in patients with NSCLC

Phase 2 evaluation of the clinical activity of MRTX849 in combination with cetuximab in patients with CRC

Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with cetuximab in patients with NSCLC

Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with cetuximab in patients with pancreatic adenocarcinoma (PDAC)

MRTX849 will be administered orally once or twice daily in a continuous regimen

MRTX849

Pembrolizumab is administered as an intravenous infusion once every 3 weeks

Cetuximab will be administered as an intravenous infusion once per week or once every 2 weeks

Afatinib will be administered orally once a day in a continuous regimen

Mirati Therapeutics Study Locator Services

Hirak Der-Torossian

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.

This study will evaluate the safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors with a KRAS G12C mutation. MRTX849 (adagrasib) is an orally-available small molecule inhibitor of KRAS G12C.

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1

Number of participants with treatment related adverse events

Objective response rate in accordance with Response Evaluation Criteria in Solid Tumors (RECIST)

Number of participants with dose limiting toxicity

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1	NCT03785249	Advanced Cancer Metastatic Canc... Malignant Neopl...	MRTX849 Pembrolizumab Cetuximab Afatinib	18 Years -	Mirati Therapeutics Inc.
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1	NCT03785249	Advanced Cancer Metastatic Canc... Malignant Neopl...	MRTX849 Pembrolizumab Cetuximab Afatinib	18 Years -	Mirati Therapeutics Inc.

Spots Global Cancer Trial Database for stk11 mutation